You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Non-surgical treatment option for pelvic organ prolapse

    SBC: REIA LLC            Topic: NICHD

    Project SummaryAbstract Reia is working to address a prevalent gynecological conditionpelvic organ prolapsePOPwhich affects more thanof women over the age ofPOP occurs when the pelvic floor connective tissue and muscles weakenallowing the uterus or vaginal walls to descendIn extreme casesthe uterus descends through the opening of the vagina and hangs outside of the bodyPOP can be treated non surgi ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Development and validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 103

    Project Summary Sanfilippo disease (mucopolysaccharidosis type III; MPS III) is a devastating neurodegenerative lysosomal storage disorder of childhood whose pathologic features are neurologic: slowing of development, severe behavioral problems, progressive cognitive decline, dementia, and decline in motor skills leading to immobility, unresponsiveness, and death. We have focused on MPS IIID cause ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. A therapeutic approach for potential prevention of aromatase inhibitor-induced bone loss

    SBC: NANOMEDIC INC            Topic: NIA

    AbstractIn this SBIR Phase I applicationour goal is to demonstrate proof of concept of our lead chelating agent as a potential therapeutic for the prevention of osteoporosis induced by aromatase inhibitorAItherapy in postmenopausal women with hormone receptor positive breast cancerAlthough AI therapy shows great improvements in cancer free and overall survivalits treated patients face a risk of os ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Advanced Dynamic Clamp for Neuroscience

    SBC: Cytocybernetics Inc            Topic: 101

    The goal of this proposal is to develop a commercial “plug and play”, user-friendly, powerful and reliable dynamic clamp system, to enable all neuronal electrophysiologists to be able to perform sophisticated dynamic clamp experiments, without any requirement for programming, engineering, or mathematical modeling skills. We will develop hardware and software specifically for neuroscience appli ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Smart Cavity Creator Drill for Lumbar Interbody Fusion

    SBC: PEER Technologies PLLC            Topic: NIBIB

    PROJECT SUMMARYABSTRACT Older patients with persistent and progressive symptoms of chronic back pain and leg pain often have a diagnosis of lumbar degenerative spondyolisthesis and undergo complex lumbar decompression and fusion surgeryOverof these procedures are performed in the United States each yearSurgery is highly effective but technically challengingOne technical challenge of fusion in spon ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. High-throughput nanoMEA-based Proarrhythmia Assay

    SBC: CURI BIO, INC.            Topic: NHLBI

    PROJECT SUMMARY Failure of new drugs at late stages of development is an extremely costly event commonly associated with the detection of unexpected arrhythmogenic properties in novel drugs Undetected arrhythmia inducing effects are also a common reason for drug withdrawal from the market As a result the FDA now mandates that all new drugs be tested for potential arrhythmogenic properties which ha ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Development of an advanced cryothermal ablation catheter and method for treating cardiac arrhythmias

    SBC: CELL PRESERVATION SERVICES INC            Topic: R

    The need for the development of new strategies for treatment of cardiac arrhythmiasincluding ventricular arrhythmiashas experienced a palpable increase in the last few yearsVentricular ArrhythmiaVAor ventricular tachycardiaVTis a severe abnormal heart rhythm which can cause death if not treated immediatelyVentricular FibrillationVFis the most serious form of VAVF is most commonly caused by VT and ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Tau oligomer platform validation using lead series candidate in htau mice

    SBC: OLIGOMERIX INC            Topic: NIA

    TITLETau oligomer platform validation using lead series candidate in htau mice PROJECT SUMMARYSBIR Funding OpportunityAdvancing Research on Alzheimerandapos s DiseaseADand Alzheimerandapos s Disease Related DementiasADRDRRPASThe long term goal of this program is to develop a disease modifyingsmall molecule drug for Alzheimer s diseaseADand related tauopathiesThere is a critical unmet need for a di ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Gene and Stem Cell-Based Treatment for Tendinopathy

    SBC: NEW YORK R & D CENTER FOR TRANSLATIONAL MEDICINE & THERAPEUTICS INC            Topic: R

    Project SummaryTendinopathy is a common chronic tendon disorder that affectsof individuals overyears oldIt is characterized by painswellingloss of functionand impaired performanceThere is currently no cure for tendinopathySpontaneous repair or treatment typically leads to scar formationresulting in a weakened tissue with reduced function and mechanical properties that may ultimately rupture with f ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD

    SBC: OLIGOMERIX INC            Topic: NIA

    PROJECT SUMMARYSBIR RRFast Track ApplicationFOA NumberPASThe long term goal of this program is to develop a disease modifyingsmall molecule drug for Alzheimer s diseaseADand AD related dementiasADRDwith tau pathologyThere is a critical unmet need for a disease modifying drugDMDfor ADChronic treatment strategies require safeeffectiveand economically feasible approaches such as small molecule drugsT ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government